Bullet Biotechnology, Inc. logo

Bullet Biotechnology, Inc.

Helping Sunesis develop kinase inhibitors to treat cancer patients. Board director for AFBS (finding treatments for NM). Husband & Dad. Bullet Biotechnology is developing, personalized Id vaccine technology - an active immunotherapy to stimulate a persons own immune system to fight against cancer and autoimmune disease.

Bullet Bio is using new sequencing and manufacturing methods to develop an idiotype cancer vaccine that it anticipates will be more effective than first-generation products.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.bulletbio.com
Founded
Disease Focus
Development Stage
STOCK CODENon Listed
Address
3815 Alameda de las,CA 94025
Pulgas Menlo Park
United States
Email
Contact Number
+1 650-278-8958

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/bullet-biotechnology-inc-” connections=”true” suffix=””]

Bullets unique proprietary technology targets B-cell lymphomas. This cancer starts with a single B cell and thus carries a unique idiotype protein, commonly known as _IdÓ. Using directed conjugation to carefully attach copies of this Id and multiple immune stimulants to the outside of a virus-like particle, Bullet Bio has created a product that trains the immune system to recognize this particular Id as a marker of cancer cells.

Till Sep 2013, Bullet Bio has raised $ 2.5 Mn USD, as Series A round funding and is planning to start clinical studies in mid 2015.